M

Mesoblast Limited
D

MESO

10.190
USD
-0.11
(-1.02%)
Pre Open
Volume
1
EPS
-1
Div Yield
-
P/E
-11
Market Cap
1,163,478,008
Related Instruments
    A
    ATHX
    0.00290
    (2.96%)
    0.10100 USD
    F
    FATE
    -0.04500
    (-2.17%)
    2.02500 USD
    More
News

Title: Mesoblast Limited

Sector: Healthcare
Industry: Biotechnology
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.